MARKET

LYEL

LYEL

Lyell Immunopharma, Inc.
NASDAQ
12.70
+0.39
+3.17%
Closed 17:03 06/09 EDT
OPEN
12.50
PREV CLOSE
12.31
HIGH
13.03
LOW
12.15
VOLUME
99.18K
TURNOVER
0
52 WEEK HIGH
45.00
52 WEEK LOW
8.46
MARKET CAP
296.34M
P/E (TTM)
-0.9788
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Lyell Immunopharma (LYEL) and BioCardia (BCDA)
TipRanks · 1d ago
Here's Why We're Watching Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
Simply Wall St · 1d ago
Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham
Dow Jones · 2d ago
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lyell Immunopharma (LYEL)
TipRanks · 2d ago
Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update
Benzinga · 2d ago
Lyell Immunopharma Issues LYL273 Safety Profile Update In Its Ongoing U.S. Phase 1 Clinical Trial In Patients With Relapsed Or Refractory Metastatic Colorectal Cancer
Benzinga · 2d ago
Lyell Immunopharma provides update on safety profile of LYL273
TipRanks · 2d ago
More
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Webull offers Lyell Immunopharma Inc stock information, including NASDAQ: LYEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYEL stock methods without spending real money on the virtual paper trading platform.